NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price, Forecast & News

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) issued its quarterly earnings data on Wednesday, February, 5th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.04 by $0.07. The biotechnology company had revenue of $29.46 million for the quarter, compared to analyst estimates of $36.63 million. Arrowhead Pharmaceuticals had a net margin of 32.56% and a return on equity of 18.21%. View Arrowhead Pharmaceuticals' Earnings History.

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for Arrowhead Pharmaceuticals.

9 equities research analysts have issued 12 month target prices for Arrowhead Pharmaceuticals' stock. Their forecasts range from $32.00 to $83.00. On average, they anticipate Arrowhead Pharmaceuticals' stock price to reach $64.13 in the next twelve months. This suggests a possible upside of 76.2% from the stock's current price. View Analyst Price Targets for Arrowhead Pharmaceuticals.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arrowhead Pharmaceuticals.

Media coverage about ARWR stock has trended neutral on Monday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arrowhead Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals saw a decline in short interest during the month of January. As of January 15th, there was short interest totalling 11,120,000 shares, a decline of 8.9% from the December 31st total of 12,200,000 shares. Based on an average daily trading volume, of 2,270,000 shares, the short-interest ratio is presently 4.9 days. Currently, 12.0% of the shares of the company are short sold. View Arrowhead Pharmaceuticals' Current Options Chain.

Some companies that are related to Arrowhead Pharmaceuticals include Genmab A/S (GNMSF), GALAPAGOS NV/S (GLPG), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ) and Dr.Reddy's Laboratories (RDY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), salesforce.com (CRM), Bristol-Myers Squibb (BMY) and Bank of America (BAC).

Arrowhead Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (4.06%), FMR LLC (1.85%), Geode Capital Management LLC (1.41%), Fiera Capital Corp (1.34%), Bank of New York Mellon Corp (1.05%) and Goldman Sachs Group Inc. (0.86%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

ARWR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Farallon Capital Management LLC, Candriam Luxembourg S.C.A., Principal Financial Group Inc., Rafferty Asset Management LLC, Goldman Sachs Group Inc., Oak Ridge Investments LLC and Fiera Capital Corp. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry and Patrick O'brien. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

ARWR stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., FMR LLC, Credit Suisse AG, American International Group Inc., Mutual of America Capital Management LLC, Retirement Systems of Alabama, Geode Capital Management LLC and Man Group plc. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARWR stock can currently be purchased for approximately $36.39.

Arrowhead Pharmaceuticals has a market capitalization of $3.70 billion and generates $168.80 million in revenue each year. The biotechnology company earns $67.97 million in net income (profit) each year or $0.69 on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe.View Additional Information About Arrowhead Pharmaceuticals.

The official website for Arrowhead Pharmaceuticals is http://www.arrowheadpharma.com/.

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]